HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HYPR
Hyperfine, Inc.
There isn't enough reported data to score HYPR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HYPR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
HYPR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HYPR PE Valuation
HYPR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HYPR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect HYPR's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HYPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.29 | +$0.23 |
| Q2 2026 | -$0.37 | +$0.15 |
| Q1 2026 | -$0.40 | +$0.14 |
| Q4 2025 | -$0.43 | +$0.13 |
| Q3 2025 | -$0.52 | +$0.05 |
| Q2 2025 | -$0.52 | +$0.06 |
| Q1 2025 | -$0.54 | +$0.05 |
| Q4 2024 | -$0.56 | +$0.06 |
HYPR has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HYPR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over HYPR on profitability, with a higher operating margin.
HYPR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $6M | +73% |
| Q2 2026 | $3.9M | +45% |
| Q1 2026 | $3.9M | +83% |
| Q4 2025 | $5.3M | +128% |
| Q3 2025 | $3.4M | -5.7% |
| Q2 2025 | $2.7M | -26% |
| Q1 2025 | $2.1M | -35% |
| Q4 2024 | $2.3M | -14% |
HYPR's revenue has grown year over year for four quarters in a row: $6M last quarter, up 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -122% | +138 points |
| Q2 2026 | -217% | +139 points |
| Q1 2026 | -219% | +291 points |
| Q4 2025 | -145% | +319 points |
| Q3 2025 | -260% | +41 points |
| Q2 2025 | -356% | -57 points |
| Q1 2025 | -510% | -187 points |
| Q4 2024 | -464% | -31 points |
HYPR's operating margin was −122% last quarter, up 138 points from the same quarter a year ago, near the top of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over HYPR on cash generation, producing positive trailing cash flow while its opponent burns cash.
HYPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.1M | -$392K |
| Q2 2026 | -$7.3M | +$1.1M |
| Q1 2026 | -$9.3M | +$471K |
| Q4 2025 | -$5.3M | +$3.1M |
| Q3 2025 | -$5.7M | +$3M |
| Q2 2025 | -$8.4M | +$1M |
| Q1 2025 | -$9.7M | +$2.9M |
| Q4 2024 | -$8.4M | +$1.8M |
HYPR has burned cash in almost every quarter: −$28M over the past year, against −$32M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HYPR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HYPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.3% | +6.3M shares |
| 1 year | +34% | +27.1M shares |
| 3 years | +48% | +34.6M shares |
HYPR has 106M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HYPR Net Leverage
HYPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HYPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.6 | Neutral |
| Stochastic | 7.7 | Oversold |
HYPR's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HYPR PE vs Healthcare Sector
HYPR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HYPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.78 | 13% below |
| 20 week MA | $0.87 | 22% below |
| 50 week MA | $1.10 | 38% below |
| 100 week MA | $1.06 | 36% below |
| 200 week MA | $1.19 | 43% below |
HYPR is in a downtrend: it's below all five of its weekly moving averages, and 43% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HYPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.1 | $9.19 | -9% |
| 2022 | $9.19 | $0.89 | -90% |
| 2023 | $0.89 | $1.12 | +26% |
| 2024 | $1.12 | $0.89 | -21% |
| 2025 | $0.89 | $1.06 | +19% |
| 2026 YTD | $1.06 | $0.68 | -36% |
HYPR has the edge over HIMS on returns for 2026, with the stronger performance.